Search for: "Sanofi GmbH"
Results 21 - 40
of 72
Sort by Relevance
|
Sort by Date
12 Aug 2019, 12:32 am
Sanofi-Aventis Deutschland Gmbh). [read post]
3 Jan 2019, 5:21 am
C00716606/01 (for the active ingredient sevelamer) and their exclusive licensee Sanofi-Aventis (Suisse) SA enforced their SPC against Swiss pharmaceutical company Salmon Pharma GmbH which had started marketing a generic version of Sanofi-Aventis’ medicament Renvela® containing the active ingredient sevelamer carbonate. [read post]
5 Feb 2018, 9:59 pm
Sanofi Aventis Deutschland GmbH PTAB Petition: IPR2017-01526; filed June 5, 2017. [read post]
6 Oct 2017, 2:34 pm
Mass. 2013) and Abbvie Deutschland GmbH v. [read post]
6 Oct 2017, 2:34 pm
Mass. 2013) and Abbvie Deutschland GmbH v. [read post]
25 Jan 2017, 11:25 pm
In referring the question on Art 3(a) as to what was required for a product to be protected by a basic patent, he stated that he was “encouraged by what the [CJEU] said in Actavis v Sanofi and Actavis v Boehringer to believe that there is a realistic prospect of the Court providing further and better guidance to that which it has hitherto provided” (para 91). [read post]
6 Apr 2015, 2:37 pm
This was not to be.Plaintiff Debra Johnson was one of fifty-two plaintiffs born in the late 1950’s or early 1960’s who filed state-court Thalidomide suits in Philadelphia against GlaxoSmithKline and certain of its affiliates (“GSK”), along with Sanofi-Aventis and/or Grunenthal GmbH. [read post]
12 Mar 2015, 11:09 am
Today's the day that many pharmaceutical patent term extension-watchers have been waiting for with feelings of optimism or anxiety: the day on which the Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. [read post]
30 Apr 2014, 10:00 pm
The Federal Circuit decision in Sanofi-Aventis Deutschland GmbH v. [read post]
24 Apr 2014, 9:59 pm
By Michael Greenfield -- On April 21, 2014, a Federal Circuit panel reiterated its interpretation and application to the chemical arts of the KSR obviousness standard. [read post]
22 Apr 2014, 7:41 am
United Parcel Serv., Inc., 665 F.3d 68, 73 (3d Cir. 2012).Sanofi-Aventis Deutschland GMBH at *12.Jury InstructionsYou may make an adverse inference in this case against Glenmark. [read post]
21 Apr 2014, 2:03 pm
According to the case, Sanofi-Aventis Deutschland GmbH is the owner of the patent at issue and Aventis Pharma S.A. is the exclusive licensee of that patent. [read post]
13 Dec 2013, 10:59 am
Among those being sued in the US are Grunenthal GMBH and American companies Merrell Richardson, now Sanofi-Aventis, and Smith, Kline and French, now GlaxoSmithKline. [read post]
22 Jul 2013, 3:51 am
It granted a licence to Sanofi-Aventis Deutschland GmbH to distribute it in Greece, under an authorisation to place it on the market granted by the competent Greek authorities in 1999. [read post]
7 Sep 2012, 3:23 pm
Today’s post is of the “this and that” variety ? [read post]
22 Feb 2012, 7:37 am
GmbH and Sanofi-aventis v. [read post]
19 Oct 2011, 3:30 am
: Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon (IPKat) (The SPC Blog) Naprelan (Naproxen) – US: Lawsuit seeks to compel FDA compliance with PDUFA user fee waiver provisions: Stat-Trade v USFDA (FDA Law Blog) OxyContin(Oxycodone) – US: Purdue Pharma files patent infringement complaint against Ranbaxy in response to Para IV certification filing (Patent Docs) Plavix (Clopidogrel) – US:… [read post]
12 Oct 2011, 3:46 am
No (FDA Law Blog) US: Patent battle over modified meganucleases heats up: Cellectis v Precision Biosciences (Holman’s Biotech IP Blog) (Patent Docs) US: Landmark NORD report on orphan drugs authored by HP&M Director shows FDA flexibility in approval (FDA Law Blog) Products Embeda (Morphine sulfate, Naltrexone hydrochloride) – US: Pfizer, Alpharma, King Pharma. file patent infringement suit against Watson following Para IV certification (Patent Docs) Exelon (Rivastigmine)… [read post]
11 Oct 2011, 3:12 am
Yesterday the IPKat celebrated the fact that two extra days were given to anyone who wants to advise the UK government whether -- and how -- to intervene in Case C-414/11 Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon , a Greek reference for a preliminary ruling by the Court of Justice of the European Union on some TRIPS-related issues (see his earlier post here). [read post]
10 Oct 2011, 7:33 am
It's Case C-414/11 Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon and it comes all the way from the Polimeles Protodikio Athinon (Greece). [read post]
